Drug intelligence / Profile preview

ceftriaxone + penicillin + gentamicin

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

This is a combination of three antibiotics—ceftriaxone, penicillin, and gentamicin—used together for the treatment of severe bacterial infections. Each component has a distinct mechanism of action: - **Ceftriaxone** is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. It has broad-spectrum activity against many Gram-negative and some Gram-positive bacteria. - **Penicillin** (referring generally to the class or specific agents like benzylpenicillin) also inhibits bacterial cell wall synthesis via binding to penicillin-binding proteins, primarily effective against Gram-positive organisms. - **Gentamicin** is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of the bacterial ribosome, inhibiting protein synthesis and causing misreading of mRNA. The combination may be used in clinical scenarios such as infective endocarditis or other serious infections where synergistic effects are desired for enhanced bactericidal activity. The addition of gentamicin can provide synergy with beta-lactam antibiotics (like ceftriaxone or penicillins), especially against certain streptococci or enterococci[1][6]. However, this triple combination is not standard for most indications; more commonly used combinations include either ceftriaxone plus gentamicin or penicillin plus gentamicin[1][6].

02

Targets

Bacterial RibosomePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ceftriaxone + penicillin + gentamicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceftriaxone + penicillin + gentamicin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call